At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 789 enrolled
Drug / intervention
Oxybutynin topical gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension
In Brief
A Phase 3 clinical trial evaluating Oxybutynin topical gel and Placebo topical gel for Overactive Bladder. Completed, enrolled 789 participants across 63 sites.
Detailed Summary
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJul 2006
Primary CompletionMay 2007
TodayJul 2026
First PostedJul 11, 2006
Enrollment StartJun 1, 2006
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 20.0 years ago
Interventions
Oxybutynin topical geldrug
1 application daily to skin for 12 weeks
Placebo topical gelother
1 application daily to skin for 12 weeks